RAINBOW

RAINBOW is a Japan-based regenerative medicine biotech developing autologous bone marrow mesenchymal stem cell therapies for chronic stroke indications. The company is focused on patients in the chronic phase of cerebral infarction and intracerebral hemorrhage, areas where treatment options are limited after the acute and subacute windows. Its lead programs are HUNS001 for chronic ischemic stroke and HUFF-01 for chronic intracerebral hemorrhage, with HUFF-01 disclosed as being in a physician-initiated Phase 1/2a trial pathway. RAINBOW also emphasizes enabling technologies for automated cell culture and a central cell processing center supply model intended to support broader commercialization of personalized cell therapies. The company originated from Hokkaido University neurosurgery and positions itself as a regenerative medicine bio-venture focused on brain repair.